RxDoctor Payments Data

Thara Abu-Mallouh, OD

Optometrist · Jacksonville, FLNPI 1790455095

Payments from drug & device makers

$3,108in general payments, 2019–2025

Across 103 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$806
  • Sun Pharmaceutical Industries Inc.$474
  • Tarsus Pharmaceuticals, Inc.$278
  • Biotissue Holdings Inc.$266
  • Bausch & Lomb Americas Inc.$232
  • Oyster Point Pharma, Inc.$194
  • plus $857 from 12 others

What the payments were for

  • Food & beverage$3,06499%
  • Entertainment$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,108 in reported general payments places this provider in the 80th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$79,391
Medicare patients
269
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine106$124,606
MieboPerfluorohexyloctane/Pf60$48,067
XiidraLifitegrast19$18,034
LumiganBimatoprost36$17,425
Alphagan PBrimonidine Tartrate36$15,853
CombiganBrimonidine Tartrate/Timolol30$12,592
RocklatanNetarsudil Mesylat/Latanoprost17$7,529
Loteprednol Etabonate23$3,766
Prednisolone Acetate51$3,315
Brimonidine Tartrate34$1,514
Latanoprost71$657
Dorzolamide Hcl18$381
MoxifloxacinMoxifloxacin Hcl12$353
Timolol Maleate35$263
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat26$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$806$170,476208 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$232$66,10179 claims
Aerie Pharmaceuticals, Inc.Rocklatan$115$7,52917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →